Tandem Diabetes Care (TNDM) FY2016 results: revenue $84 million, up 15.6% on the year
Tandem Diabetes Care Inc. (TNDM) reported revenue of $84 million for fiscal 2016, the year ended 31 December 2016, up 15.6% on the year before. Net income was -$83 million, and diluted earnings per share $-27.30. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2019.
Revenue
$84 million
+15.6% on the year
FY2012FY2016
Operating margin
-92.6%
-94.7% a year earlier
FY2012FY2016
Net income
-$83 million
FY2012FY2016
Diluted EPS
-$27.30
FY2012FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
84.2
72.8
49.7
+15.6%
Cost of revenue
60.7
46.3
34.5
+31.1%
Gross profit
23.6
26.6
15.2
-11.2%
Gross margin
28.0%
36.5%
30.7%
Research and development
18.8
17.0
15.8
+10.9%
Selling, general and administrative
82.8
78.6
75.1
+5.4%
Operating income
-78.1
-69.0
-75.7
Operating margin
-92.6%
-94.7%
-152.2%
Pre-tax income
-83.5
-72.4
-79.5
Income tax
-0.0
0.0
0.1
Net income
-83.4
-72.4
-79.5
Net margin
-99.0%
-99.4%
-159.9%
Diluted EPS
-$27.30
-$25.00
-$34.20
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
-61.2
-58.8
-61.4
Capital expenditure
8.9
5.8
4.4
+54.9%
Free cash flow
-70.1
-64.5
-65.8
Free cash flow margin
-83.2%
-88.6%
-132.3%
Cash from investing
10.4
n/a
n/a
Cash from financing
52.3
n/a
n/a
Depreciation and amortisation
5.5
4.8
4.4
+13.7%
Share-based compensation
11.7
13.1
15.0
-11.0%
Shares outstanding at period end
3m
3m
2m
+2.8%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
-5.9
63.5
54.6
Debt
81.1
30.2
30.0
+168.9%
Other liabilities
37.2
31.1
21.9
+19.7%
Total liabilities and equity
112
125
106
-9.9%
Fixed assets
18.4
15.5
12.6
+18.6%
Investments
8.9
28.0
36.1
-68.4%
Trading assets
n/a
n/a
36.1
Cash and equivalents
44.7
43.1
31.2
+3.7%
Receivables
11.2
14.1
7.7
-20.5%
Inventory
21.2
17.5
11.9
+20.8%
Other assets
8.1
6.5
n/a
+24.4%
Total assets
112
125
106
-9.9%
10-K for the year ended 31 December 2016, filed 26 February 2019: the filing.